Download PDF
Rehabilitation (Stuttg) 2024; 63(06): 376-388
DOI: 10.1055/a-2154-3672
CME-Fortbildung

Gefäßmedizinische Rehabilitation bei Patienten mit peripher arterieller Verschlusskrankheit (pAVK)Von der spezialisierten Form zur eigenen Fachabteilung

Vascular rehabilitation for patients with peripheral arterial occlusive disease
Gesine Dörr
› Further Information
Also available at
    Permissions and Reprints

Patienten mit pAVK sind hinsichtlich der Verordnungshäufigkeit von Reha-Maßnahmen [1] und der Kontrolle der Risikofaktoren im Vergleich zu Patienten mit koronarer Herzerkrankung (KHK) bei Hausärzten schlechter eingestellt [2–4]. Sie erkennen das erhöhte kardiovaskuläre Risiko und die damit verbundene Notwendigkeit einer Lebensstiländerung und Therapietreue nicht in dem Maße wie Patienten mit KHK [5]. Dieser Beitrag widmet sich der Frage, warum die Entwicklung spezialisierter gefäßmedizinischer Versorgungsstrukturen angestrebt wurde und wie sich dies zu einem eigenständigen Gebiet der Rehabilitation weiterentwickeln kann und sollte.

Abstract

Compared to patients with coronary heart disease, patients with PAD have a poorer attitude towards general practitioners with regard to the frequency of prescribing rehabilitative measures and controlling risk factors. The patients themselves do not perceive the increased cardiovascular risk and thus the need for lifestyle changes and compliance to the same extent as patients with coronary heart disease.

The “Rehabilitation clinic with vascular expertise” certificate defines the criteria for fulfilling the specific structural and process requirements for vascular medicine.

Due to the paradigm shift and the increasing importance of conservative therapy for patients with intermittent claudication, vascular rehabilitation can be the start of or support for the implementation of conservative therapy and thus ensure long-term patient compliance with regard to the implementation of drug therapy, lifestyle changes and the sustainability of gait training. For hospitalized patients, vascular rehabilitation closes the gap to more sustainable aftercare.

Increasing demand will promote the development of vascular medical rehabilitation and increase awareness on the part of payers. This process is being scientifically monitored.

The goal should be a care structure for patients with PAD that is regulated on an outpatient basis as part of a separate or adapted DMP program, that includes the quality standards of the “Interdisciplinary Vascular Centers” on an inpatient basis and that includes vascular medical rehabilitation with subordinate vascular sports groups.

From the point of view of rehabilitation, the aim is for vascular rehabilitation to be recognized as an independent specialist area by the payers.

Schlüsselwörter

gefäßmedizinische Rehabilitation - periphere arterielle Verschlusskrankheit (pAVK) - Sekundärprävention - Gehtraining - Zertifikation - strukturiertes Programm

Keywords

vascular medical rehabilitation - peripheral artery disease - secondary prevention - walking training - certification - Structural programm


Publication History

Article published online:
11 December 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Falk J, Haaf HG, Brünger M. Rehabilitation of Patients with Peripheral Arterial Disease in the Context of Guideline Recommendations. Rehabilitation (Stuttg) 2019; 58: 225-233
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Bauersachs R, Zeymer U, Brière JB. et al. Burden of Coronary Artery. Disease and Peri pheral Artery Disease: A Literature Review. Cardiovasc Ther 2019; 2019: 8295054
    CrossrefPubMedSearch in Google Scholar
  • 3 Criqui MH, Langer RD, Fronek A. et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386
    CrossrefPubMedSearch in Google Scholar
  • 4 Kalbaugh CA, Loehr L, Wruck L. et al. Frequency of Care and Mortality Following an Incident Diagnosis of Peripheral Artery Disease in the Inpatient or Outpatient Setting: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc 2018; 7: e007332
    CrossrefPubMedSearch in Google Scholar
  • 5 Armstrong EJ, Chen DC, Westin GG. et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc 2014; 3: e000697
    CrossrefPubMedSearch in Google Scholar
  • 6 Diehm C, Schuster A, Allenberg JR. et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172: 95-105
    CrossrefPubMedSearch in Google Scholar
  • 7 Diehm C, Lange S, Darius H. et al. Association of low ankle brachial index with high mortality in primary care. Eur Heart J 2006; 27: 1743-1749
    CrossrefPubMedSearch in Google Scholar
  • 8 Sampson UKA, Fowkes FGR, McDermott MM. et al. A global and regional burden of death and disability from peripheral artery disease 21 World Regions, 1990 to 2010. Glob Heart 2014; 9: 145-158
    CrossrefPubMedSearch in Google Scholar
  • 9 Abtan J, Bhatt DL, Elbez Y. et al. Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. Clin Cardiol 2017; 40: 710-718
    CrossrefPubMedSearch in Google Scholar
  • 10 Jones WS, Patel MR, Rockman CB. et al. Association of the ankle-brachial index with history of myocardial infarction and stroke. Am Heart 2014; 167: 499-505
    CrossrefPubMedSearch in Google Scholar
  • 11 Resnick HE, Lindsay RS, McGrae McDermott M. et al. Relationship of High and Low Ankle Brachial Index to All-Cause and Cardiovascular Disease Mortality: The Strong Heart Study. Circulation 2004; 109: 733-739
    CrossrefPubMedSearch in Google Scholar
  • 12 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339
    CrossrefPubMedSearch in Google Scholar
  • 13 Hirschl M. Antithrombotische Therapie bei PAVK. J Cardiol 2003; 10: 152-156
    PubMedSearch in Google Scholar
  • 14 Subherwal S, Patel MR, Kober L. et al. Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. Eur J Prev Cardiol 2015; 22: 317-325
    CrossrefPubMedSearch in Google Scholar
  • 15 AWMF. S3-Leitlinie Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. 2024. AWMF-Registernummer 065-003. Im Internet: https://register.awmf.org/de/leitlinien/detail/065-003; Stand: 29.09.2024
    PubMed
  • 16 Mancia G, Kreutz R, Brunström M. et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023; 41: 1874-2071
    CrossrefPubMedSearch in Google Scholar
  • 17 AWMF. S3-Leitlinie Nationale VersorgungsLeitlinie (NVL) Typ-2-Diabetes. Registernummer nvl-001. Im Internet: https://register.awmf.org/de/leitlinien/detail/nvl-001; Stand: 29.09.2024
    PubMed
  • 18 Feringa HHH, Karagiannis SE, van Waning VH. et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg 2007; 45: 936-943
    CrossrefPubMedSearch in Google Scholar
  • 19 Arya S, Khakharia A, Binney ZO. et al. Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease. Circulation 2018; 137: 1435-1446
    CrossrefPubMedSearch in Google Scholar
  • 20 Bonaca MP, Nault P, Giugliano RP. et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease – Insights From the FOURIER Trial. Circulation 2018; 137: 338-350
    CrossrefPubMedSearch in Google Scholar
  • 21 Baviere M, Bertelè V, Avanzini F. et al. Peripheral arterial disease: Changes in clinical outcomes and therapeutic strategies in two cohorts, from 2002 to 2008 and from 2008 to 2014. A population-based study. Eur J Prev Cardiol 2018; 25: 1735-1743
    CrossrefPubMedSearch in Google Scholar
  • 22 Mach F, Baigent C, Catapano AL. et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2020; 41: 111-188
    CrossrefPubMedSearch in Google Scholar
  • 23 Gebauer K, Wintersohl K, Kraska R. et al Medication-based secondary prevention in patients with peripheral arterial occlusive disease: An analysis based on secondary data. Herz 2021; 46: 280-286
    CrossrefPubMedSearch in Google Scholar
  • 24 März W, Dippel FW, Theobald K. et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis 2018; 268: 99e107
    CrossrefPubMedSearch in Google Scholar
  • 25 Subherwal S, Patel MR, Kober L. et al. Missed Opportunities Despite Improvement in Use of Cardioprotective Medications Among Patients With Lower-Extremity Peripheral Artery Disease, Underuse Remains. Circulation 2012; 126: 1345-1354
    CrossrefPubMedSearch in Google Scholar
  • 26 Aboyans V, Bauersachs R, Mazzolai L. et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J 2021; 42: 4013-4024
    CrossrefPubMedSearch in Google Scholar
  • 27 Bonaca MP, Bauersachs RM, Anand SS. et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382: 1994-2004
    CrossrefPubMedSearch in Google Scholar
  • 28 Espinola-Klein C. Antithrombotic Therapy in Lower Extremity Arterial Disease and Aortic Diseases. Aktuel Kardiol 2022; 11: 560-564
    Thieme ConnectPubMedSearch in Google Scholar
  • 29 Anand SS, Bosch J, Eikelboom JW. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219-229
    CrossrefPubMedSearch in Google Scholar
  • 30 Lamberts M, Lip GYH, Ruwald MH. et al. Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease: a nationwide cohort study. J Am Coll Cardiol 2014; 63: 2689-2698
    CrossrefPubMedSearch in Google Scholar
  • 31 AWMF. S3-Leitlinie Kardiologische Rehabilitation im deutschsprachigen Raum Europas Deutschland, Österreich, Schweiz (D-A-CH). 2020. AWMF-Registernummer 133-001. Im Internet: https://register.awmf.org/de/leitlinien/detail/133-001; Stand: 29.09.2024
    PubMed
  • 32 Hussain MA, Al-Homran M, Mamdani M. et al. Efficacy of a Guideline-Recommended Risk-Reduction Program to Improve Cardiovascular and Limb Outcomes in Patients With Peripheral Arterial Disease. JAMA Surg 2016; 151: 742-750
    CrossrefPubMedSearch in Google Scholar
  • 33 Mazzolai L, Belch J, Venermo M. et al. Exercise therapy for chronic symptomatic peripheral artery disease. Eur Heart J 2024; 45: 1303-1321
    CrossrefPubMedSearch in Google Scholar
  • 34 Bonaca MP, Creager MA. Pharmacological Treatment and Current Management of Peripheral Artery Disease. Circ Res 2015; 116: 1579-1598
    CrossrefPubMedSearch in Google Scholar
  • 35 Hagemann D, Fokkenrood HJ, Gommans LN. et al. Supervised exersice therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev 2018; 4: CD005263
    CrossrefPubMedSearch in Google Scholar
  • 36 Pymer S, Ibeggazene S, Palmer J. et al. An updated systematic review and meta-analysis of home-based exercise programs for individuals with intermittent claudication. J Vasc Surg 2021; 74: 2076-2085
    CrossrefPubMedSearch in Google Scholar
  • 37 Parmenter BJ, Mavros Y, Ritti Dias R. et al. Resistance training as a treatment for older persons with peripheral artery disease: a systematic review and meta-analysis. Br J Sports Med 2020; 54: 452-461
    CrossrefPubMedSearch in Google Scholar
  • 38 Jansen SCP, Abaraogu OU, Lauret GJ. et al. Modes of exercise training for intermittent claudication. Cochrane Database Syst Rev 2020; 8: CD009638
    CrossrefPubMedSearch in Google Scholar
  • 39 Veiga C, Pedras S, Oliveira R. et al. A systematic review on smartphone use for activity monitoring during exercise therapy in intermittent claudication. J Vasc Surg 2022; 76: 1734-1741
    CrossrefPubMedSearch in Google Scholar
  • 40 Gardener AW, Montogomery PS, Parker DE. Optimal exercise program length for patients with claudication: a randomized controlled trail. J Vasc Surg 2012; 55: 1346-1354
    CrossrefPubMedSearch in Google Scholar
  • 41 Parmenter BJ, Dieberg G, Phipps G. et al. Exercise training for health-related quality of life in peripheral artery disease: A systematic review and meta-analysis. Vasc Med 2015; 20: 30-40
    CrossrefPubMedSearch in Google Scholar
  • 42 Jansen SCP, Hoorweg BBN, Hoeks SE. et al. A systematic review and meta-analysis of the effects of supervised exercise therapy on modifiable cardiovascular risk factors in intermittent claudication. J Vasc Surg 2019; 69: 1293-1308
    CrossrefPubMedSearch in Google Scholar
  • 43 Sakamoto S, Yokoyama N, Tamori Y. et al. Patients with peripheral artery disease who complete a 12-week exersice training program show a reduced cardiovacular mortality and morbidity. Circ J 2009; 73: 167-173
    CrossrefPubMedSearch in Google Scholar
  • 44 Li Y, Rother U, Rosenberg Y. et al. A prospective survey study on the education and awareness about walking exercise amongst inpatients with symptomatic peripheral arterial disease in Germany. Vasa 2023; 52: 218-223
    CrossrefPubMedSearch in Google Scholar
  • 45 Rother U, Dörr G, Malyar N. et al. How German vascular surgeons and angiologists judge walking exercise for patients with PAD Results from a nationwide survey amongst 743 members of two major scientific societies. Vasa 2023; 52: 224-229
    CrossrefPubMedSearch in Google Scholar
  • 46 Kühnl A, Knipfer E, Lang T. et al. Krankenhausinzidenz, stationäre Versorgung und Outcome der peripheren arteriellen Verschlusskrankheit und arteriellen Thrombose/Embolie in Deutschland von 2005 bis 2018. Gefässchirurgie 2020; 25: 433-445
    CrossrefPubMedSearch in Google Scholar
  • 47 Fakhry F, Spronk S, van der Laan L. et al. Endovascular revascularization an supervised exercise for peripheral artery disease and intermittent claudication – an randomized clinical trial. JAMA 2015; 314: 1936-1944
    CrossrefPubMedSearch in Google Scholar
  • 48 Klaphake S, Fakhry F, Rouwet EV. et al. Long-term follow-up of randomized clinical trial comparing endovascular revascularization plus supervised exercise with supervised exercise only in intermittent claudication. Ann Surg 2022; 276: e1036-e1043
    CrossrefPubMedSearch in Google Scholar
  • 49 Djerf H, Millinger J, Falkenberg M. et al. Absence of Long-Term Benefit of Revascularization in Patients with Intermittent Claudication Five-Year Results From the IRONIC Randomized Controlled Trial. Circ Cardiovasc Interv 2020; 13: e008450
    CrossrefPubMedSearch in Google Scholar
  • 50 Stauber S, Guéra V, Barth J. et al. Psychosocial outcome in cardiovascular rehabilitation of peripheral artery disease and coronary artery disease patients, 2013. Vasc Med 2013; 18: 257-262
    CrossrefPubMedSearch in Google Scholar
  • 51 [38] Hoffmann U, Weiss N, Czihal M. et al. Hrsg. Klinische Angiologie. Springer Referenz Medizin; Berlin: Springer; 2025
    CrossrefSearch in Google Scholar
  • 52 Meng K, Westphal R, Marx M. et al. Reha-Verlaufseffekte bei Rehabilitand:innen mit peripherer arterieller Verschlusskrankheit zum Rehabilitationsende. DRV-Schriften 2024; 130: 289-291
    PubMedSearch in Google Scholar